Skip to main content
SpringerLink
Log in

Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The IKAROS family zinc finger 1 (IKZF1) gene is frequently altered in adults with B cell acute lymphoblastic leukemia (ALL). Although many studies have indicated that IKZF1 alterations might be associated with poor outcomes in adults with ALL, the results remain controversial. A previous meta-analysis demonstrated the negative prognostic significance of IKZF1 deletion in ALL. However, most of the included studies (14 out of 15) were conducted in pediatric patients with ALL, and age was identified as a significant source of heterogeneity. Thus, performing the present meta-analysis provides valuable information to further elucidate the prognostic value of IKZF1 deletion in adults with ALL. Eight studies were identified that had been published prior to August 1, 2016. The studies included a total of 1008 patients. Hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS)/relapse-free survival (RFS)/progression-free survival (PFS)/event-free survival (EFS) were pooled to estimate the prognostic power of IKZF1 deletion. Pooled HRs suggested that IKZF1 deletion had a negative impact on both OS (HR = 1.40, 95% CI 1.13–1.73) and DFS/RFS/PFS/EFS (HR = 1.67, 95% CI 1.28–2.17) in the overall population. Subgroup analyses indicated that IKZF1 deletion could independently predict unfavorable OS (HR = 1.60, 95% CI 1.25–2.06) and DFS/RFS/PFS/EFS (HR = 1.67, 95% CI 1.28–2.17) in BCR-ABL1-negative but not in BCR-ABL1-positive B cell ALL patients. Our meta-analysis suggests that IKZF1 deletion is a poor prognostic factor for adults with B cell ALL and may be more valuable in BCR-ABL1-negative B cell ALL patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Moorman AV (2016) New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica 101(4):407–416

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dias A, Kenderian SJ, Westin GF et al (2016) Novel therapeutic strategies in acute lymphoblastic leukemia. Curr Hematol Malig Rep 11(4):253–264

    Article  PubMed  Google Scholar 

  3. Al Ustwani O, Gupta N, Bakhribah H et al (2016) Clinical updates in adult acute lymphoblastic leukemia. Crit Rev Oncol Hematol 99:189–199

    Article  PubMed  Google Scholar 

  4. Olsson L, Johansson B (2015) Ikaros and leukaemia. Br J Haematol 169(4):479–491

    Article  CAS  PubMed  Google Scholar 

  5. Wang H, Ouyang H, Lai L et al (2014) Pathogenesis and regulation of cellular proliferation in acute lymphoblastic leukemia—the role of Ikaros. J Buon 19(1):22–28

    PubMed  Google Scholar 

  6. Tokunaga K, Yamaguchi S, Iwanaga E et al (2013) High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia. Eur J Haematol 91(3):201–208

    Article  CAS  PubMed  Google Scholar 

  7. Beldjord K, Chevret S, Asnafi V et al (2014) Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 123(24):3739–3749

    Article  CAS  PubMed  Google Scholar 

  8. Iacobucci I, Storlazzi CT, Cilloni D et al (2009) Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114(10):2159–2167

    Article  CAS  PubMed  Google Scholar 

  9. Martinelli G, Iacobucci I, Storlazzi CT et al (2009) IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 27(31):5202–5207

    Article  CAS  PubMed  Google Scholar 

  10. Clappier E, Grardel N, Bakkus M et al (2015) IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children’s Leukemia Group study 58951. Leukemia 29(11):2154–2161

    Article  CAS  PubMed  Google Scholar 

  11. Olsson L, Ivanov Ofverholm I, Noren-Nystrom U et al (2015) The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. Br J Haematol 170(6):847–858

    Article  CAS  PubMed  Google Scholar 

  12. van der Veer A, Zaliova M, Mottadelli F et al (2014) IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 123(11):1691–1698

    Article  PubMed  Google Scholar 

  13. van der Veer A, Waanders E, Pieters R et al (2013) Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122(15):2622–2629

    Article  PubMed  PubMed Central  Google Scholar 

  14. Olsson L, Castor A, Behrendtz M et al (2014) Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia 28(2):302–310

    Article  CAS  PubMed  Google Scholar 

  15. Asai D, Imamura T, Suenobu S et al (2013) IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Med 2(3):412–419

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Yao QM, Liu KY, Gale RP et al (2016) Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. BMC Cancer 16:269

    Article  PubMed  PubMed Central  Google Scholar 

  17. Fang Q, Zhao X, Li Q et al (2016) IKZF1 alterations and expression of CRLF2 predict prognosis in adult Chinese patients with B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 1–11. doi:10.1080/10428194.2016.1180682

  18. Ribera J, Morgades M, Zamora L et al (2015) Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer 121(21):3809–3817

    Article  CAS  PubMed  Google Scholar 

  19. Kim M, Park J, Kim DW et al (2015) Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. Bone Marrow Transplant 50(3):354–362

    Article  CAS  PubMed  Google Scholar 

  20. Jia M, Wang ZJ, Li JY et al (2014) The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: an updated meta-analysis. Cancer Biomark 14(6):493–503

    CAS  PubMed  Google Scholar 

  21. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7), e1000097

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16

    Article  PubMed  PubMed Central  Google Scholar 

  23. Moorman AV, Schwab C, Ensor HM et al (2012) IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 30(25):3100–3108

    Article  PubMed  Google Scholar 

  24. Dupuis A, Gaub MP, Legrain M et al (2013) Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia 27(2):503–507

    Article  CAS  PubMed  Google Scholar 

  25. O’Reilly J, Russell LJ, Cooney J et al (2013) Unravelling the prognostic effect of IKZF1 deletions and IGH@-CRLF2 in adult acute lymphoblastic leukaemia. Pathology 45(6):609–612

    Article  PubMed  Google Scholar 

  26. Mullighan CG, Miller CB, Radtke I et al (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453(7191):110–114

    Article  CAS  PubMed  Google Scholar 

  27. Zaliova M, Zimmermannova O, Dorge P et al (2014) ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia 28(1):182–185

    Article  CAS  PubMed  Google Scholar 

  28. Clappier E, Auclerc MF, Rapion J et al (2014) An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28(1):70–77

    Article  CAS  PubMed  Google Scholar 

  29. Ge Z, Gu Y, Zhao G et al (2016) High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement. Oncotarget. doi: 10.18632/oncotarget.10437

  30. Chiaretti S, Brugnoletti F, Messina M et al (2016) CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leuk Res 41:36–42

    Article  CAS  PubMed  Google Scholar 

  31. Yamashita Y, Shimada A, Yamada T et al (2013) IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 60(10):1587–1592

    Article  CAS  PubMed  Google Scholar 

  32. Palmi C, Vendramini E, Silvestri D et al (2012) Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 26(10):2245–2253

    Article  CAS  PubMed  Google Scholar 

  33. Pieters R, de Groot-Kruseman H, Van der Velden V et al (2016) Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group. J Clin Oncol 34(22):2591–2601

    Article  PubMed  Google Scholar 

  34. Short NJ, Jabbour E, Sasaki K et al (2016) Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504–507

    Article  CAS  PubMed  Google Scholar 

  35. Ravandi F, Jorgensen JL, O’Brien SM et al (2016) Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172(3):392–400

    Article  CAS  PubMed  Google Scholar 

  36. Borowitz MJ, Wood BL, Devidas M et al (2015) Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood 126(8):964–971

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Salek C, Folber F, Fronkova E et al (2016) Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. Eur J Haematol 96(3):276–284

    Article  CAS  PubMed  Google Scholar 

  38. Marke R, Havinga J, Cloos J et al (2016) Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia 30(7):1599–1603

    Article  CAS  PubMed  Google Scholar 

  39. Vitanza NA, Zaky W, Blum R et al (2014) Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer 61(10):1779–1785

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Churchman ML, Low J, Qu C et al (2015) Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell 28(3):343–356

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Song C, Gowda C, Pan X et al (2015) Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood 126(15):1813–1822

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu, 610041, People’s Republic of China

    Wanhua Zhang, Pu Kuang, He Li & Fengjuan Wang

  2. Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu, 610041, People’s Republic of China

    Yu Wang

Authors
  1. Wanhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pu Kuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. He Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fengjuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wanhua Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, W., Kuang, P., Li, H. et al. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis. Ann Hematol 96, 215–225 (2017). https://doi.org/10.1007/s00277-016-2869-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2869-6

Keywords

Search

Navigation